These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 37994343)
1. Construction and evaluation of a novel prognostic risk model of aging-related genes in bladder cancer. Wang D; Ning H; Wu H; Song Y; Chu Y; Liu F; Zhao Z; Wu F; Lyu J Curr Urol; 2023 Dec; 17(4):236-245. PubMed ID: 37994343 [TBL] [Abstract][Full Text] [Related]
2. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer. Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764 [TBL] [Abstract][Full Text] [Related]
3. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer. Pan G; Xie H; Xia Y Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551 [TBL] [Abstract][Full Text] [Related]
4. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer. Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465 [TBL] [Abstract][Full Text] [Related]
5. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer. Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P Front Oncol; 2023; 13():972558. PubMed ID: 37064115 [TBL] [Abstract][Full Text] [Related]
6. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer. Tan Z; Fu S; Zuo J; Wang J; Wang H Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832 [TBL] [Abstract][Full Text] [Related]
7. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma. Chen L; Lin J; Wen Y; Chen Y; Chen CB Front Oncol; 2023; 13():1291720. PubMed ID: 38023241 [TBL] [Abstract][Full Text] [Related]
8. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer. Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model. Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787 [TBL] [Abstract][Full Text] [Related]
10. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer. Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230 [TBL] [Abstract][Full Text] [Related]
11. Identification and Validation of an Individualized Prognostic Signature of Bladder Cancer Based on Seven Immune Related Genes. Qiu H; Hu X; He C; Yu B; Li Y; Li J Front Genet; 2020; 11():12. PubMed ID: 32117435 [TBL] [Abstract][Full Text] [Related]
12. Construction and validation of a prognostic model for bladder cancer based on disulfidptosis-related lncRNAs. Yang X; Zhang Y; Liu J; Feng Y Medicine (Baltimore); 2024 Jul; 103(27):e38750. PubMed ID: 38968515 [TBL] [Abstract][Full Text] [Related]
13. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence. Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881 [TBL] [Abstract][Full Text] [Related]
14. Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer. Zheng Z; Mao S; Zhang W; Liu J; Li C; Wang R; Yao X Front Oncol; 2020; 10():542492. PubMed ID: 33392066 [TBL] [Abstract][Full Text] [Related]
15. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer. Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T Front Genet; 2021; 12():696912. PubMed ID: 34512722 [No Abstract] [Full Text] [Related]
16. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer. Wang Z; Tu L; Chen M; Tong S BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144 [TBL] [Abstract][Full Text] [Related]
17. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis. Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402 [TBL] [Abstract][Full Text] [Related]
18. A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database. Hu J; Wang L; Li L; Wang Y; Bi J BMC Cancer; 2022 Nov; 22(1):1158. PubMed ID: 36357874 [TBL] [Abstract][Full Text] [Related]
19. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer. Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433 [TBL] [Abstract][Full Text] [Related]
20. Construction and verification of a novel hypoxia-related lncRNA signature related with survival outcomes and immune microenvironment of bladder urothelial carcinoma by weighted gene co-expression network analysis. Cai D; Zhou Z; Wei G; Wu P; Kong G Front Genet; 2022; 13():952369. PubMed ID: 36118856 [No Abstract] [Full Text] [Related] [Next] [New Search]